Immunopathogenesis of Psoriasis;Immunpathogenese der Psoriasis

JDDG - Journal of the German Society of Dermatology

Volumn 1, Issue 7, 2003, Pages 524-532

  Ghoreschi, Kamran ^a   Röcken, Martin ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NONE

Author keywords

Endothelial cells; Genetics; Immune deviation; Interleukin 4; Keratinocytes; Th1 lymphocytes; Triggering factors

Indexed keywords

AUTOANTIGEN; BACTERIAL PROTEIN; GAMMA INTERFERON; HISTOCOMPATIBILITY ANTIGEN; AUTOANTIBODY; CYTOKINE; EPITOPE;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DERMIS; ENDOTHELIUM CELL; GENETIC SUSCEPTIBILITY; HUMAN; INFLAMMATION; KERATINOCYTE; MAST CELL; NEUTROPHIL; PSORIASIS; REVIEW; STREPTOCOCCUS INFECTION; TH1 CELL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; GENETICS; IMMUNOGENETICS; IMMUNOLOGY; JOINT; METABOLISM; PHYSIOLOGY; PSORIATIC ARTHRITIS; RISK FACTOR; SKIN;

ARTHRITIS, PSORIATIC; AUTOANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPITOPES; HUMANS; IMMUNITY, CELLULAR; IMMUNOGENETICS; JOINTS; PSORIASIS; RISK FACTORS; SKIN; TH1 CELLS;

EID: 3042600680     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1610-0387.2003.03010.x     Document Type: Review

References (56)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
2. Barker JN. Genetic aspects of psoriasis. Clin Exp Dermatol 2001; 26: 321-325.
3. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999; 455: 221-225.
4. Tamir A, Wolf R, Brenner S. Exacerbation and induction of psoriasis by angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 1994; 30: 1045.
5. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000; 1: 159-165.
6. Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol 2000; 25: 351-352.
7. Griffiths CE, Richards HL. Psychological influences in psoriasis. Clin Exp Dermatol 2001; 26: 338-342.
8. Higgins E. Alcohol, smoking and psoriasis. Clin Exp Dermatol 2000; 25: 107-110.
9. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145-149.
10. Prinz JC. Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26: 326-332.
11. Weisenseel P, Laumbacher B, Besgen P, Ludolph-Hauser D, Herzinger T, Röcken M, Wank R, Prinz JC. Streptococcal infection distinguishes different types of psoriasis. J Med Genet 2002; 39: 767-768.
12. Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. Br J Dermatol 2001; 145: 886-890.
13. Morris A, Rogers M, Fischer G, Williams K. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol 2001; 18: 188-198.
14. Gladman DD. Current concepts in psoriatic arthritis. Curr Opin Rheumatol 2002; 14: 361-366.
15. Gonzalez S, Martinez-Borra J, Lopez-Vazquez A, Garcia-Fernandez S, Torre-Alonso JC, Lopez-Larrea C. MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. J Rheumatol 2002; 29: 973-978.
16. Gudjonsson JE, Karason A, Antonsdottir AA, Runarsdottir EH, Gulcher JR, Stefansson K, Valdimarsson H. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118: 362-365.
17. Schröder JM, Christophers E. Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 1986; 87: 53-58.
18. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997; 14: 145-153.
19. Okubo Y, Koga M. Peripheral blood monocytes in psoriatic patients over-produce cytokines. J Dermatol Sci 1998; 17: 223-232.
20. De Rie MA, Zonneveld IM, Witkamp L, Van Lier RA, Out TA, Bos JD. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol 1996; 76: 357-360.
21. Gangemi S, Merendino RA, Guarneri F, Minciullo PL, DiLorenzo G, Pacor M, Cannavo SP. Serum levels of interleukin-18 and s-ICAM-1 in patients affected by psoriasis: preliminary considerations. J Eur Acad Dermatol Venereol 2003; 17: 42-46.
22. Szabowski A, Maas-Szabowski N, Andrecht S, Kolbus A, Schorpp-Kistner M, Fusenig NE, Angel P. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 2000; 103: 745-755.
23. Ruckert R, Asadullah K, Seifert M, Budagian VM, Arnold R, Trombotto C, Paus R, Bulfone-Paus S. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol 2000; 165: 2240-2250.
24. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999; 54: 1-7.
25. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555.
26. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin a and tacrolimus. Scand J Immunol 2003; 57: 93-98.
27. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, Solodkina G, Grossman R, Gisoldi E, Phillips S, Neisler HM, Krueger JG. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000; 43: 595-604.
28. Weinshenker BG, Bass BH, Ebers GC, Rice GP. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol 1989; 20: 1132-1133.
29. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-447.
30. Kanamori H, Tanaka M, Kawaguchi H, Yamaji S, Fujimaki K, Tomita N, Fujisawa S, Ishigatsubo Y. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol 2002; 71: 41-44.
31. Snowden JA, Heaton DC. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmuniry. Br J Dermatol 1997; 137: 130-132.
32. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG: The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113: 752-759.
33. Lin WJ, Norris DA, Achziger M, Kotzin BL, Tomkinson B. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J Invest Dermatol 2001; 117: 1546-1553.
34. Schön MP, Detmar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat Med 1997; 3: 183-188.
35. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T-cells induces psoriasis. Am J Pathol 1999; 155: 145-158.
36. Ackermann L, Harvima IT, Pelkonen J, Ritamaki-Salo V, Naukkarinen A, Harvima RJ, Horsmanheimo M. Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br J Dermatol 1999; 140: 624-633.
37. Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, Kollias G, Kunkel SL, Hultner L, Röcken M. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000; 192: 1441-1452.
38. Jiang WY, Chattedee AD, Raychaudhuri SP, Raychaudhuri SK, Farber EM. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol 2001; 40: 699-703.
39. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994; 94: 202-209.
40. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999; 141: 1054-1060.
41. Nickoloff BJ. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Investig Dermatol Symp Proc 2000; 5: 67-73.
42. Ormerod AD, Weller R, Copeland P, Benjamin N, Ralston SH, Grabowksi P, Herriot R. Detection of nitric oxide and nitric oxide synthases in psoriasis. Arch Dermatol Res 1998; 290: 3-8.
43. Röcken M, Urban JF, Shevach EM. Infection breaks T-cell tolerance. Nature 1992; 359: 79-82.
44. Röcken M, Racke M, Shevach EM. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today 1996; 17: 225-231.
45. Friedrich M, Sterry W, Asadullah K. Novel developments in the systemic treatment of psoriasis. JDDG 2003; 1: 12-21.
46. Mrowietz U. Therapie der Psoriasis mit Biologicals. Hautarzt 2003; 54: 224-229.
47. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002; 29: 18-26.
48. Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T-cells. J Exp Med 1993; 178: 1655-1663.
49. Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Röcken M. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000; 60: 1515-1520.
50. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 1990; 126: 351-355.
51. Reich K, Brück M, Grafe A, Vente C, Neumann C, Garbe C. Treatment of psoriasis with interleukin-10. J Invest Dermatol 1998; 111: 1235-1236.
52. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Docke WD. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101: 783-794.
53. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
54. Kalden JR. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res 2002; 4 Suppl 2: 34-40.
55. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, Schwertschlag U, Dorner AJ, Krueger JG. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104: 1527-1537.
56. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlöndorff D, Plewig G, Sander CA, Röcken M. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9: 40-46.